Financial Performance - Preliminary unaudited total revenue for 2024 is $701.0 million, up from $675.0 million in 2023, representing a growth of approximately 3.7%[1] - Fourth quarter EXPAREL net product sales reached $147.7 million in 2024, compared to $143.9 million in 2023, indicating a growth of about 2.6%[3] - Full-year EXPAREL net product sales totaled $549.0 million in 2024, a slight increase from $538.1 million in 2023, with average daily volume growth of 4%[10] - Full-year ZILRETTA net product sales were $118.1 million in 2024, compared to $111.1 million in 2023, reflecting a growth of approximately 6.3%[10] - The company reported a five percentage point gross margin improvement over 2024, indicating enhanced profitability[4] Strategic Objectives - The company aims to achieve five growth-oriented objectives by 2030 under its "5x30" plan, focusing on operational excellence and innovative non-opioid pain therapies[2] - The clinical pipeline is expanding with five novel programs currently in development, enhancing the company's growth potential[4] - The company is establishing five partnerships, including pipeline and commercial agreements, to bolster its market position[4] Product Development and Market Expansion - The company is focusing on the market acceptance and growth potential of EXPAREL, ZILRETTA, and iovera°, with plans to expand their use to additional indications[26] - The company is evaluating and developing additional product candidates utilizing its proprietary multivesicular liposome (pMVL) drug delivery technology[26] - The company is pursuing supplemental New Drug Applications and premarket notification 510(k)s with the U.S. Food and Drug Administration, as well as Marketing Authorization Applications with the European Medicines Agency[26] - The company is assessing its commercialization and marketing capabilities to enhance the success of its products[26] Future Reporting and Financial Guidance - Pacira plans to report complete financial results for the fourth quarter and full-year 2024 in the first quarter of 2025, along with financial guidance[6] Risk Management and Compliance - The company acknowledges known and unknown risks that could cause actual results to differ from forward-looking statements[27] - The company does not intend to update or revise forward-looking statements unless required by law[27] Operational Plans - The company is planning to complete capital projects and integrate any future acquisitions into its existing business[26] - The company is monitoring the recoverability of its deferred tax assets and assumptions related to contingent consideration payments[26] - The company anticipates funding or benefits from its share repurchase program[26]

Core Insights - Pacira BioSciences reported record revenues of $701 million for the full year 2024, marking a 4% increase from $675 million in 2023 [6][14] - The company experienced a full-year GAAP net loss of $99.6 million, which translates to a loss of $2.15 per share, compared to a net income of $42 million in 2023 [10][14] - Adjusted EBITDA for the full year was $223.9 million, a 4% increase from $214.5 million in 2023 [10][14] Financial Performance - Fourth quarter revenues reached $187.3 million, a 3% increase from $181.2 million in Q4 2023 [6][8] - EXPAREL net product sales for 2024 were $549 million, a 2% increase from $538.1 million in 2023 [10][14] - ZILRETTA net product sales increased by 6% to $118.1 million in 2024, up from $111.1 million in 2023 [10][14] - Total operating expenses for 2024 were $774.3 million, compared to $587.3 million in 2023, which included a goodwill impairment of $163.2 million [10][14] Strategic Initiatives - The company launched a new Five-Year Plan (5x30) aimed at transitioning into an innovative biopharmaceutical organization, with goals to reach over 3 million patients annually and achieve double-digit revenue growth by 2030 [6][8] - In February 2025, Pacira acquired the remaining 81% equity stake in GQ Bio Therapeutics for approximately $32 million to enhance its growth strategy [6][8] - The company appointed Laura Brege as Chair of the Board in January 2025, as part of its commitment to board refreshment [6][8] Product Development and Regulatory Updates - The FDA approved a new iovera° Smart Tip in December 2024 for managing chronic low back pain, expanding the product's application [8] - A new patent for EXPAREL was issued, expected to provide protection until July 2044, supporting long-term exclusivity [8] - Data for PCRX-201 indicated sustained efficacy in treating moderate to severe osteoarthritis of the knee, with a well-tolerated safety profile [8]

Core Viewpoint - Pacira BioSciences has acquired an 81% equity stake in GQ Bio Therapeutics for approximately $32 million, enhancing its capabilities in innovative biopharmaceuticals and eliminating future milestone payment obligations, which could amount to $64 million [1][5]. Group 1: Acquisition Details - The acquisition includes an upfront payment of $18 million, with an additional $8 million to be paid over three years and a post-closing indemnity holdback of $6 million [1]. - GQ Bio's high-capacity adenovirus (HCAd) gene therapy vector platform will be integrated into Pacira's operations, focusing on the development of PCRX-201 and other products [4][12]. Group 2: Strategic Importance - The acquisition aligns with Pacira's "5x30" plan to transition into a leading innovative biopharmaceutical organization, addressing unmet patient needs in chronic pain management [3]. - The HCAd platform is expected to significantly enhance the efficiency of gene delivery, allowing for the treatment of prevalent musculoskeletal diseases like osteoarthritis [6][7]. Group 3: Financial Implications - By eliminating future milestone payments, the transaction is projected to provide substantial financial benefits to Pacira, including a specific milestone payment of $4.5 million related to the initiation of a Phase 2 clinical trial for PCRX-201 [5]. - The HCAd platform's efficiency in gene delivery is anticipated to result in a commercially attractive cost of goods profile, enabling the production of thousands of doses in a single batch [7][8]. Group 4: Clinical Development - PCRX-201 is currently in clinical development for knee osteoarthritis, showing promising results in a Phase 1 study with sustained improvements in pain and function over two years [9]. - The product candidate utilizes an inflammation-responsive promoter to enhance the body's natural response to inflammation, potentially offering a novel treatment approach [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Pacira BioSciences, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Pacira securities is from August 2, 2023, to August 8, 2024, and the lead plaintiff deadline is March 14, 2025 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the specified deadline to serve as lead plaintiff [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Background - The lawsuit alleges that statements made by Pacira during the Class Period were misleading, particularly regarding the patent protections on Exparel, which were claimed to be critical for the company's growth [4]. - It is asserted that Pacira was aware of the weaknesses in its patent protections, particularly following a court ruling in favor of eVenus on June 6, 2023, yet continued to publicly affirm the strength of its patent [4]. - The lawsuit claims that when the true nature of the patent protections became known, investors suffered damages [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pacira BioSciences, Inc. following the invalidation of its '495 patent, which has led to significant stock price declines and investor losses [2][4][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $75,000 in Pacira between August 2, 2023, and August 8, 2024, to discuss their legal options [1]. - The firm is reminding investors of the March 14, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against Pacira [2]. Group 2: Patent Invalidation Impact - On August 9, 2024, a New Jersey District Court invalidated Pacira's '495 patent, ruling that eVenus did not infringe on the patent due to obviousness and anticipation [4]. - The invalidation announcement surprised investors, leading to a dramatic stock price decline from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, representing a decline of over 47% in a single day [5]. Group 3: Class Action Details - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [6]. - Any member of the putative class may move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [6].

Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial losses for the company [1]. Summary by Sections Legal Issues - Pacira's U.S. Patent No. 11,033,495, related to its main product Exparel, was ruled invalid by the court, which raises concerns about the validity of other patents held by the company [1]. - The invalidation of the '495 patent could result in more generic competitors entering the market and increased litigation costs for Pacira [1]. Financial Impact - Following the announcement of the patent ruling, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for a class action lawsuit, with a deadline for lead plaintiff applications set for March 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2].

Group 1 - Pacira BioSciences, Inc. is committed to delivering innovative, non-opioid pain therapies to transform patients' lives [1][2] - The company has three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and ioveraº® [2] - Pacira is advancing the development of PCRX-201, a novel locally administered gene therapy for treating prevalent diseases like osteoarthritis [2] Group 2 - Pacira will participate in the Raymond James 46th Annual Institutional Investors Conference on March 5th at 10:25 AM ET [3] - The company will also attend the Barclays 27th Annual Global Healthcare Conference on March 12th at 8:00 AM ET [3]

Core Viewpoint - Wall Street analysts anticipate Pacira (PCRX) will report quarterly earnings of $0.86 per share, reflecting a year-over-year decline of 3.4%, while revenues are expected to be $184.01 million, an increase of 1.5% from the previous year [1] Earnings Projections - Changes in earnings projections are crucial for predicting investor reactions to the stock, with empirical studies showing a strong correlation between earnings estimate trends and short-term stock price movements [2] Analyst Forecasts - Analysts project that 'Revenue- Net product sales- EXPAREL' will reach $145.33 million, indicating a year-over-year change of +1% [4] - The consensus for 'Revenue- Net product sales- ZILRETTA' is $30.72 million, reflecting a +7% change from the year-ago quarter [4] - For 'Revenue- Net product sales- iovera', analysts estimate $6.36 million, which represents a +5.4% change from the previous year [4] Total Revenue Estimates - The combined estimate for 'Revenue- Total net product sales' is projected to be $183.38 million, indicating a year-over-year change of +2% [5] Stock Performance - Pacira shares have seen a -1.6% change over the past month, compared to a -1.8% move in the Zacks S&P 500 composite, with a Zacks Rank 1 (Strong Buy) suggesting expected outperformance in the near future [5]

Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 2, 2023, and August 8, 2024 [1] Group 1: Lawsuit Details - The lawsuit was initiated following a press release on August 9, 2024, where Pacira announced the invalidation of its U.S. Patent No. 11,033,495 related to its main product Exparel, which constitutes approximately 80% of the company's revenue [2] - The invalidation of the '495 patent raises concerns about the validity of other patents held by Pacira, potentially leading to increased competition from generic products and higher litigation costs [2] - Following the announcement, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial losses for the company [1]. Summary by Relevant Sections Company Overview - Pacira BioSciences, Inc. (NASDAQ: PCRX) is primarily known for its product Exparel, which constitutes approximately 80% of its revenue [1]. Legal Issues - A lawsuit against eVenus resulted in the court ruling that Pacira's U.S. Patent No. 11,033,495 (the '495 patent) is not valid, meaning eVenus is not infringing on it [1]. - The invalidation of the '495 patent raises concerns about the validity of Pacira's other patents, potentially leading to more generic competitors entering the market and increased litigation costs [1]. Stock Performance - Following the announcement of the patent invalidation, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for a class action lawsuit, with a deadline for lead plaintiff appointment set for March 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Legal Representation - The Gross Law Firm is leading the class action, emphasizing its commitment to protecting investors' rights against deceitful business practices [3].